Lantern Pharma (LTRN) Current Assets (2019 - 2026)

Lantern Pharma (LTRN) has reported Current Assets for 8 consecutive years, with $8.5 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Current Assets fell 50.82% year-over-year to $8.5 million; the trailing twelve-month figure through Jun 2026 stood at $8.5 million (down 50.82% YoY), and the FY2025 full-year result was $10.8 million, down 57.21% from the prior year.
• Current Assets rose to $8.5 million in Q2 2026 per LTRN's latest filing, from $7.1 million in the prior quarter.
• Across five years, Current Assets topped out at $67.7 million in Q1 2022 and bottomed at $7.1 million in Q1 2026.
• Historically, Current Assets has averaged $36.6 million across 5 years, with a median of $37.4 million in 2024.
• The sharpest annual moves came in 2022 and 2026: Current Assets dropped 17.97% in 2022, then slumped 66.11% in 2026.
• Over 5 years, Current Assets stood at $58.7 million in 2022, then declined by 26.19% to $43.3 million in 2023, then tumbled by 41.75% to $25.2 million in 2024, then sank by 57.21% to $10.8 million in 2025, then dropped by 21.7% to $8.5 million in 2026.
• According to Business Quant data, Current Assets over the past three periods registered $8.5 million, $7.1 million, and $10.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.